# FreeStyle Libre 2 Discharge Trial

Study · id `cardio:ct-nct05822232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05822232](<https://clinicaltrials.gov/study/NCT05822232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05822232

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05822232. Randomized; no masking; primary purpose prevention. Start 2022-08-17 (actual); primary completion 2024-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05822232, source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)
- Started: 2022-08-17 (actual) (ClinicalTrials.gov record NCT05822232, source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)
- Primary completion: 2024-04-30 (anticipated) (ClinicalTrials.gov record NCT05822232, source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)
- Completion: 2024-04-30 (anticipated) (ClinicalTrials.gov record NCT05822232, source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05822232, source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05822232-2023-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: FreeStyle Libre 2 Discharge Trial
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypoglycemia
- Intervention (Device): FreeStyle Libre 2 CGM
- Intervention (Device): FreeStyle Libre Pro blinded CGM
- Intervention (Device): FreeStyle Precision Neo blood glucose meter
- Lead sponsor: Palo Alto Medical Foundation
- Lead sponsor class: OTHER
- Collaborator: Abbott Diabetes Care
- Collaborator class: INDUSTRY
- Collaborator: Emory University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Abbott Diabetes Care (`cardio:org-abbott-diabetes-care`)
- Registry lists this organization as a collaborator: Emory University (`cardio:org-emory-university`)

## Provenance

Content hash: fb88606ef3f2a74e890cc1da6dcb7cd8c9a392c0743409dd9bd9414a1b5c0719
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
